Cesalatamig Data to Be Presented at SITC Meeting
The Phase 1/2 trial results for this investigational cancer therapy will be unveiled on November 7 in Phoenix.
Updated on Oct. 29, 2026 in Cancer
OncoC4 is set to present findings from an ongoing Phase 1/2 clinical trial for the experimental bispecific antibody cesalatamig. The oral presentation will take place in Phoenix on November 7, 2026, during the 41st Annual Meeting of the Society for Immunotherapy of Cancer.
Why it matters
Cesalatamig is a novel PD-1/VEGF bispecific antibody currently being studied for potential therapeutic use in cancer treatment. The upcoming presentation of clinical data offers a look at progress in this specific drug development pathway following its September 2026 FDA Fast Track designation.
The upcoming presentation at the 41st Annual Meeting of the Society for Immunotherapy of Cancer will feature abstract 1187, covering interim results from the ongoing Phase 1/2 BiPAVE-001 trial. Specific efficacy and safety profiles remain under investigation until the formal presentation.
The players
OncoC4
A Rockville-based biopharmaceutical company focused on the development of novel immunotherapies including bispecific antibodies.
Dr. Kai He
A clinical investigator who will present the findings of the cesalatamig trial.
Society for Immunotherapy of Cancer
A professional medical society that hosts annual scientific meetings to advance research in cancer immunotherapy.
The details
Cesalatamig is a bispecific antibody designed to target both PD-1 and VEGF. By simultaneously inhibiting these two pathways, the molecule aims to modulate the immune system's response to tumors while also addressing the vascular environment that supports tumor growth. Clinical trial outcomes from the ongoing BiPAVE-001 study will clarify how this dual-targeting mechanism performs in humans.
Timeline
September 2026: The FDA granted Fast Track designation to cesalatamig.
October 29, 2026: OncoC4 announced the scheduled abstract presentation.
November 7, 2026: Clinical Oral Abstract Session 2 begins at 1:45 PM MST in Phoenix.
Health Landscape
The drug's FDA Fast Track designation signifies that the candidate has met regulatory criteria for expedited development, aligning with the broader industry focus on accelerating promising immuno-oncology therapies. This research program sits among current efforts to develop complex bispecific antibodies that target multiple cancer-growth pathways.
This development is an early-stage research update, meaning it does not currently change standard treatment options for patients. Those interested in novel cancer therapies should discuss clinical trial eligibility and the status of experimental agents like cesalatamig with an oncologist.
The takeaway
The study of bispecific antibodies like cesalatamig reflects an ongoing trend in targeting multiple immune and tumor pathways simultaneously. Patients interested in innovative treatment approaches should track the progress of clinical trials through their physician or accredited oncology centers.
Further reading
For more information on the latest developments in oncology research, visit Cancer.
